Product Name: Roflumilast CAS NO:162401-32-3
Chemical & Physical Properties:
Appearance : white to off-white powder
Boiling Point:430.6℃ at 760 mmHg
Flash Point: 214.2℃
Roflumilast is an oral selective phosphodiesterase 4 (PDE4) inhibitor, a benzamide compound, and the only phosphatase IV (PDE-4) inhibitor approved for oral treatment of respiratory diseases. . By selectively inhibiting PDE4, it blocks inflammatory response signal transmission, thereby inhibiting lung tissue damage caused by respiratory diseases such as COPD and asthma. It has been shown to inhibit COPD-related inflammation with a new mode of action. Roflumilast is a once-a-day tablet and is the first drug for the new treatment of severe COPD. It is also the first oral anti-inflammatory drug specially developed for COPD patients. Its unique properties help to better manage patients with chronic obstructive pulmonary disease: when combined with bronchodilators to treat patients with the most severe chronic obstructive pulmonary disease, Roflumilast can provide additional benefits to further reduce symptoms and disease progression. Benefits, thus becoming the first drug to target patients with a specific phenotype of chronic obstructive pulmonary disease, that is, patients with severe airflow limitation associated with long-term cough and sputum and with a history of repeated disease deterioration.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.